Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
09:56am, Tuesday, 09'th Nov 2021
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies: Q3 Earnings Insights
08:12am, Tuesday, 09'th Nov 2021
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
08:00am, Tuesday, 02'nd Nov 2021
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
08:00am, Friday, 08'th Oct 2021
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms
Intra-Cellular says clinical study shows its schizophrenia drug helps patients with bipolar disorder
09:19am, Monday, 27'th Sep 2021
Shares of Intra-Cellular Therapies Inc. ITCI, -1.12% gained 1.5% in premarket trading on Monday after the company said clinical data showed that its experimental treatment for bipolar disorder reduced
In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder a
Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms (Circulati
Why Intra-Cellular Therapies Was Weak This Week
04:48pm, Friday, 13'th Aug 2021
The company's second-quarter net loss was a bit deeper than analysts expected.
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2021 Results - Earnings Call Transcript
02:47pm, Monday, 09'th Aug 2021
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2021 Results - Earnings Call Transcript
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
10:50am, Monday, 09'th Aug 2021
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -7.59% and 8.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies: Q2 Earnings Insights
07:52am, Monday, 09'th Aug 2021
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year to ($0.85), which missed the
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
07:30am, Monday, 09'th Aug 2021
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
10:27am, Wednesday, 02'nd Jun 2021
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2021 Results - Earnings Call Transcript
01:21pm, Monday, 10'th May 2021
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2021 Results - Earnings Call Transcript
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
09:46am, Monday, 10'th May 2021
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 19.75% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
